GYM BioSciences Inc. (YM) is a biopharmaceutical company engaged in the development of products for the treatment of patients with cancer. The Company owns or in-licenses substances or products in order to advance them along the regulatory and clinical pathways toward commercial approval. It conducts and out-sources clinical trials and it out-sources the manufacture of clinical materials to third parties. Its portfolio of products in active clinical development includes three anti-cancer agents in numerous clinical trials. Its small molecule Janus Kinase (JAK) 1/2 inhibitor, CYT387, is in clinical development for myeloproliferative neoplasm-tumors (MPNs) and may have applications in solid tumors, as well as inflammatory disease. Its monoclonal antibody, nimotuzumab, is being developed in 11 clinical trials by YM and its licensees in numerous solid tumor indications. On March 9, 2010, Cytopia Limited changed its name to YM BioSciences Australia Pty Ltd.
